Theracryf PLC Share Chat (TCF)

While you should never buy or sell from a post on a chat board, dismissing bear opinions simply because you are long something is asking for a lesson in individual money contraction!

I was long and wrong here for too long really, but I never entirely dismissed the bear posters; I did pay less attention to those who appeared too intense and repetitive in their negativity, or those who veered from bear to bull for no seemingly strong reason. But, like today, when I am long something, I pay particular attention to the considered bear posts.

Probably even more so now, after a few soakings. And AIM is for the occasional short term punt, never a long term hold investment, as far as I am concerned now. Unlike a few years ago.

And especially if a BOD do not buy big from their own pocket, like the lifestyle ones here.

Most recent evidence to support this thesis/opinion, especially in this particular space: VAL and even CREO.

Great posts DSFLAT

I will read on this evening

Https://www.mdpi.com/2227-9059/12/5/991

STALICLA publishes on identification of first autism subgroup and matching treatment

Geneva, Switzerland, May 8, 2024 – STALICLA SA, a Swiss neuro precision biotech company, has provided proof-of-concept clinical data for DEPI (Databased Endophenotyping Patient Identification), its neuro precision discovery platform, enabling the identification of biological subgroups of patients with Autism Spectrum Disorder (ASD) and matching treatments, in a study published last week in Biomedicines

https://stalicla.com/media/news/stalicla-publishes-on-first-precision-medicine-study

DSFlat, that’s the first time I’ve seen you show any negativity about this share. For what it’s worth I think you were really unlucky with your original investment, I shared your thoughts entirely in late 2022. £10m in the bank, a $163m deal signed, guidance of $6m to be received by end of 2023, lots in the pipeline for SFX-01, Juvenesense deal coming along and to go active. I was sure this was a multi bagger when investing in late 2022. I really believed I would treble my money here.

How have we got from there to where we are today, share price going from 5p to 0.7p and troubled waters. Your subsequent top ups are questionable though, I know you wanted to average down your buy in price but pumping more money in just exposes you to potential larger losses. I just hope you haven’t put all your eggs in one basket.

I can’t agree with your comment that my post would be pointless as it is condescending if Stalicla weren’t messing TCF about. Alarm bells have been sounding here for a year now but people chose to ignore them. The delay now with Stalicla has been brewing for a year, it was clear something wasn’t right when EVG changed their guidance about when they would receive the $5.5m milestone payments a year ago without any explanation and that they have never factored in Stalicla money into any forecasts. Everyone includes expected income into their forecast.

As for my message being condescending, that wasn’t my intention. I have lost money here, we all have, it’s simply stating it’s a shame that on these message boards (not just EVG/TCF) when we all have the same goal to make money, that people dismiss anyone with negative criticism of a share as trolling rather than value an alternative opinion. For example I saw Kingalf talk up OBD on this and the OBD messageboard. I was intrigued. Then I saw xxxinvestorxxx write his sceptical views on the share which made me realise I don’t fancy it. Did I see xxxinvestorxxx as a troll? No. I valued his thoughts and it did actually save me money as I was tempted to invest a small amount.

I would add that sitting on some heavy paper losses It's not all Rainbows and Unicorns for me and I hope Stalicla or some other news gets me out of a flipping big hole.

Too late for me to repent

Come on Huw do something to get this festering turd going in the right direction ffs

With respect BJ39 if Stalicla hadn't flucked around your post would be as pointless as it is condescending ;-)

Well said!

This share continues to be incredibly frustrating with the lack of updates and clarity of key issues.

It’s interesting just how quiet the posters are who were so positive of EVG/TCF and so critical of posters who were cautious and critical of the share for many different reasons.

I bought in at approx 5p after the Stalicla deal was announced and sold at 2.55p due to the confusion and change in information about when milestone payments would be received and the worry that a share placing would occur due to running out of funds. I was also unhappy at the lack of information about why Juvenesense pulled out and that the board instead of being disappointed said it was a good thing as they wanted to pursue bigger fish. Add to that the fibs about the board were not allowed to buy shares for legal reasons.

The amount of criticism Kingalf and I received on here, from being called trolls, talking nonsense, told to leave, etc was so disappointing. We see it a lot in life these days, look at JK Rowling how she has been bullied, attempted to be censored, cancelled, discredited for her views on gender ID. Same here, if you are critical of the share you get the same treatment. It’s bizarre, I don’t understand it. Even when I’m invested I value negative concerns far more than positive rampers. I don’t understand why such hostility towards people who post criticism and negativity of a share when it’s clearly deserved.

I hope you posters who were critical of us will change how you see posters who are sceptical, cautious and critical of a share in future and instead of being insulting will have an open mind and debate it. You may have saved a lot of money had you been more open minded.

TheraCryf PLC formally known as Eve is a clinical stage therapeutics company that is developing a new generation of innovative therapeutics in oncology and behavioral brain disorders.

Their strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma1.

The company was formerly known as Evgen Pharma plc, and it acquired Chronos Therapeutics in April 20241.

TheraCryf’s clinical asset is SFX-01, a patented sulforaphane-based medicine1. They are also working on neuropsychiatry assets that use novel chemistry to address highly relevant targets in brain health1.

TheraCryf is focusing on developing commercially successful products, targeting certain cancers and behavioural brain disorders1. They have several ongoing projects, including:

SFX-01 and glioblastoma: Pre-clinical models show positive data for SFX-01 on tumour shrinkage and extended survival times1.

NCE Ox-1 in Addiction and Anxiety Disorders: TheraCryf has a candidate stage antagonist molecule targeting the orexin 1 receptor with high specificity1.

NCE Atypical DAT inhibitor in Fatigue and Narcolepsy: The Company has a candidate stage atypical inhibitor of the brain dopamine transporter mechanism1.

We just need one of the big fish in the Pharma world to take a second look at Theracryf and Stalicla

https://www.stalicla.com/media/events

Presumably Stalicla were exhibiting this week at LSX..

https://informaconnect.com/lsx-world-congress/

Aren't they always? Lol. Meanwhile, another II that chose to be diluted, rather than participate in the recent dilutive raise, is RNS'd. Better late than never.

This reminds me of a scene in that series Sharpe, starring Sean Bean...'if we can wipe the name, perhaps we may wipe the shame'. Or words to that effect.

Different of course. The fictional South Essex regiment in that series had a track record of success before Wellington took the decision to change the name in that episode.

This one would better represent a battalion led by Sir Henry Simmerson exclusively :)

"we are actively seeking non-dilutive funding for our acquired programmes."

I think that’s a really good possible theory investor. I agree that there is no sign that the deal is going to be pulled but there is some definite delay in payments and what you describe could be spot on. $5.5m is a lot of money to find.

It would also explain why TCF issued only a meagre share placing which only covered the cost of acquiring this new company.

I think it will go into phase 2 and this share price can increase 300% from here.

Stalicla also updated their website to account for the name change. This was another opportunity to ditch SFX-01, but again, they have not done so. When they raised their first round of series B funds, Stalicla noted that they plan a larger funding round later in the year (slated as Q3 24). Maybe they have been holding off paying Theracryf until they are closer to finalising such a deal.

When you consider the raise was for $17.2m, and after IND acceptance from the FDA, Stalicla would be due to pay TCF $5.5m (Over 30% of the raise), it does make business sense for Stalicla to slow STP-2 progress down to ensure they have the funds to remain solvent. Unfortunately, it is us Theracryf shareholders taking the brunt of Stalicla's decision. The delay doesn't mean the Stalicla deal is dead, in fact I would argue that the longer it goes on for the more likely it is that Stalicla are simply buying themselves time to get additional funding.

Things should move quickly to progress STP-2 to Phase 2 once/if Stalicla confirm that the $500k is going to be paid. IND is likely to be applied for shortly after the Phase 1 data has been fully reviewed as there should be little additional work needed for this to happen. Unfortunately, from Stalicla's side, it makes sense to prioritise their newly acquired STP-7 asset to Phase 3, and STP-1 to Phase 2 before STP-2 due to the payments they need to make to Theracryf.

I'm still confident that Stalicla will progress STP-2 to Phase 2, we just don't know the timing.

STALICLA Appoints Dr. Thomas Blaettler, MD

Appointment will propel STALICLA’s mission to develop their late-stage clinical assets for precision brain disease treatment.

https://www.stalicla.com/media/news/STALICLA-Appoints-Dr.-Thomas-Blaettler

Stalicla stated they would be strengthening their team when they raised recently, which they have done.

They had Blaettler come through with the Theracryf deal ;-)

I've not given up hope that the partnership with Stalicla will go into phase 2 and either the milestone payments of $5.5m will be paid or Stalicla will aim to buy out TCF. Stalicla have not pulled the plug on the deal and on their website, in the pipeline section the arrow suggests that this is ready to go into phase 2. Until we get news on what is happening there is still hope but the fact it is May 2024 and still no further milestone payments or updates following on from the dispute notice is alarming and confusing. One RNS with a positive update on this will send this share price up past 2p, could be even 3p.

You have to wonder what are all the staff doing at TCF, it seems like any work done on SFX-01 is being done by external organisations. I think this is the reason EVG/TCF acquired this new company as they had run out of work. They couldn't afford to acquire this company without raising extra capital.

Don't give up hope yet.

CJ39: The lack of updates since the final nail in the coffin Stal update (as far as I was concerned) is entirely in line with my expectations.

Indeed, the fund raise and name change underpin the belief that this is a full-blown lifestyle company, removing any doubt in my mind now anyway.

Dreadful dilution. Minimal inside buying. Overcompensated management, which is even less forgivable in the current circumstances.

The reason for the name change and the purchase of that entity, offering a rationale for the raise....well, it is not fooling many people it seems.

Or if you want to be more diplomatic - it is not winning over many hearts and minds.

But as I always say, this is AIM. Spin the wheel if you feel like doing so.

I did wonder with the name change would we get some news of updates to get things going again but what was I thinking, of course not. Who thought on February 9th when we had the RNS advising that Evgen had issued a dispute notice that we would get to May 1st with no updates? They really do see shareholders as an inconvenience and that we don’t need to know what’s happening.

On a side note, I see on this site that they have already removed EVG’s whole page on here so can’t access old chat or RNS’s from here.

Looks like the change of name has not tricked investors into parting with any more of their cash!

Maybe the BOD can put their hands in their pockets again and buy a decent amount this time, rather than the chump change as per the last RNS.

Ultimately, it looks like the market has got wise to these types of outfits.

CJ, Yes looks as if this is the new (second hand) bulletin board for Evgen Pharma or Theracryf as it now is. Share price of 0.80p is (sadly) is the pre name change price of EVG.

It’s alright in here isn’t it. See the last people in here left a decade ago. They left some cheese in the fridge but I found some tea bags in the cupboard.

Let’s hope this new name brings about a change in fortunes, it’s been a very poor last 18 months. But I have bought back in, 200k shares at 0.8p. It’s a bit of a gamble but good news with the Stalicla deal would see this rise past 2p easily. Still have no idea what’s going on with it but there has to be news soon.

Good spot BD!

The Directors of Terra Catalyst Fund ("the Company") wish to announce that the Net Asset Value for the Company as of 31st July 2014 was 201.2264 pence per share. Looks like one or two folk spotted this Cayman Islands special ;-)

Could be nothing